Investigation of Genetic Determinants of Capecitabine Toxicity
The purpose of this study is to identify possible genetic polymorphisms that contribute to specific toxicities associated with capecitabine (hand-foot syndrome, diarrhea, and neutropenia).
Additionally, this study will look at gene polymorphisms in patients experiencing the toxicities of interest, the frequency of polymorphisms and differences in drug metabolism.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama - Birmingham
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Georgetown University
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
Evanston, Illinois, United States, 60201
- Northshore University Healthsystem
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Cancer Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina - Chapel Hill
-
Durham, North Carolina, United States, 27708
- Duke University
-
-
Tennessee
-
Nashville, Tennessee, United States, 73232
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- M.D. Anderson Cancer Center
-
Houston, Texas, United States, 77030
- Baylor University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- women with breast cancer in whom single agent capecitabine therapy is being considered
- aged 18 years and older
Exclusion Criteria:
- patients who have previously received capecitabine are excluded
- patients cannot be receiving capecitabine in combination with another cancer chemotherapy; concurrent use of trastuzumab is not permitted; concurrent use of zoledronic acid is allowed
- serum albumin less than 3.0 g/dL within the last 30 days
- creatinine clearance (CrCL) or glomerular filtration rate (GFR) less than 60 mL/min [/body surface area (BSA)] (within the last 30 days)
- inability to understand and give informed consent to participate
- patients with a history of inflammatory bowel disease requiring therapy or patients with chronic diarrhea syndromes or paralytic ileus
- patients with prior or concurrent pelvic irradiation
- patients who use an ostomy for fecal excretion
- there is no limit on the number of prior chemotherapies; the decision to use capecitabine is determined solely by the treating physician
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Capecitabine
Women with breast cancer receiving capecitabine as treatment for their breast cancer.
|
Paper or telephone questionnaire to report specific side-effects associated with their breast cancer treatment weekly
Blood samples for research on DNA before starting treatment and after 4 cycles of treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Genetic variants of toxicity
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Time to toxicity based on genetics
Time Frame: 2 years
|
2 years
|
|
Multiple genetic variants as predictors
Time Frame: 2 years
|
2 years
|
|
Genome-wide association (potential)
Time Frame: 2 years
|
2 years
|
|
Correlative sample collection
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Peter H O'Donnell, MD, University of Chicago
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 09-056-B
- TBCRC 015 (Other Identifier: Translational Breast Cancer Reseach Consortium)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.